Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SPDR S&P Biotech ETF (XBI)

NYSEArca - NYSEArca Delayed Price. Currency in USD
Add to watchlist
116.27+1.22 (+1.06%)
At close: 04:00PM EST
116.60 +0.33 (+0.28%)
After hours: 04:54PM EST
Advertisement
Sign in to post a message.
  • s
    snwth
    I have done a bit of research on XBI, and see that an uptrend run should be out there around the corner. Here are some highlights I found:

    - from technical point of view, XBI has been in a straight downtrend from last local peak (beginning of Nov.) for more than 3 weeks;
    - this seems the second longest straight downtrend in last a couple of years (the longest was the one starting from the peak on Feb);
    - this downtrend lost more a bit more than 14% that is the second worst after the Feb drop;
    - it dropped ~34% from the peak on Feb.;
    - moving average shows a picture with 5<10<20<30<50<100<200 in daily chart with evenly distributed gap between MA curves;
    - this moving average picture indicates an upcoming bull in general;
    - from data point of view, first its major components have similar curve pictures;
    - LABD has been in the NYSE/Threshold list for several months, this implies that LABD has been over shorted;
    - finally shorts will have to buy back LABD to cover their short position because of being over shorted;
    - in order to lower down LABD so that shorts can buy to cover at low, a typical approach is to raise its underlying's price that is XBI that will drive the price of LABD low;
    - current XBI's RSI value is very low (28 today) which is way below normal low RSI (14 days close) of ETF's;
    - current RSI (7 days close) value is even at 16 that is extremely low;
    - trading volume in last two weeks are in an uptrend picture;
    - MACD's are around very low levels in this downtrend cycle (the 3rd lowest to last year March and this Feb.);
    - the entire healthcare sector is in a similar downward cycle, and we can expect a bouncing back at anytime;
    - such a positive move from the entire healthcare sector will force XBI to move even higher due to its beta;

    According to what I observed above, IMO, XBI should have a bull cycle coming up at anytime.
    GLTL!
    Bullish
  • E
    Ez$
    $SLS conversation
    $SLS Market Cap 107.068M
    Gps Phase 3 AML data 7 months from now that could be worth $3-5B

    All have partnership or industry comps $JAZZ $XBI $MRKR $ADAP $AXSM
    3 Trial Results coming in DEC and JAN $BMY $RHHBY $MRK
  • Z
    Zuj
    $GALT conversation
    All of $XBI biotech sector is down. Other sectors at unsustainable p/e. Now is the time to pick up value bios before the profit taking from other sectors flows back into bio.
    Bullish
  • k
    kC
    $SLS conversation
    $Xbi up 1% today - Funds buying sls shares from short sellers.
    70% Sold Short yesterday at the bottom to hold this down barely 3% -- lets see what happens today -- Rock Bottom
  • A
    Artur
    It presents mild disease with symptoms being sore muscles and tiredness for a day or two not feeling well. So far, we have detected that those infected do not suffer loss of taste or smell. They might have a slight cough. There are no prominent symptoms. Of those infected some are currently being treated at home," Coetzee said

    Was the next strain just fatigue? Have we forgotten about serious diseases like cancer, giving all the money to treat fatigue? Panic in the market is caused artificially
    Bullish
  • C
    Cured
    $SLS conversation
    Actually great for $XBI bio in general WSJ NEWS EXCLUSIVE HEALTH
    Omicron Unlikely to Cause Severe Illness in Vaccinated People, BioNTech Founder Says
    Variant could lead to more infections but vaccinated people likely remain protected from severe disease, Ugur Sahin says
    Bullish
  • A
    A
    $SLS conversation
    Market has to realize technology does not save lives: they could be an enabler but $xbi saves lives, be it covid ($mrna, $ocgn, $bntx) or cancer ($sls, $glsi). time to shift some tesla boom to where it matters, for survival…
  • J
    John
    If you own this etf you should get a discount on anti-depression meds
  • S
    Stephens
    $SLS conversation
    10 Signs of an impending buyout
    1. Dead silence from management and IR on all fronts for months.
    2. Multiple amazing trial data releases in June of 2021 More Coming in Dec and January
    3. Licensing deal and cash from December of 2020 with $200 million 3DMeds deal.
    4. Market maker's unwillingness to let it move higher even in the face of outweighing inflow.
    5. Mass manipulation to push the share price down for accumulation prior to the deal being released.
    6. S3 ATM offering to shift the balance of the negotiations in SLS favor with cash on hand vs bidder.
    7. Three open positions on the website that still haven't been filled, also another bargaining chip vs the bidder.
    8. Not a single negative data release yet constant down pressure vs comparable companies.
    9. Institutions like Vanguard, Blackrock, and Susquehanna are still loaded big given the size of the float.
    10. Existing relationships and trials with Roche, Merck, Bristol-Myers, and 3DMeds.

    $XBI

    $AAPL

    $AMZN
    Bullish
  • S
    Scamster_CEO_Exposer
    $SLS conversation
    officially down 50% from (13.15+) where cantor and co sold. way to go. this is how to loot investors…

    @real you can attribute to $xbi down or whatever but bottomline no other stock is down this much in the past 6 months. Angelos takes the crown as the ripper of investors’ money.
  • A
    A
    $SLS conversation
    As an old chapter closes, expect good news soon (between now and eoy).

    Now I think time for company to strictly restrict their therapies to non shorts, no hedge funds (sorry citadel and others that did short). Shorting life-savers especially on misinformation should be banned.

    We wouldn’t have been here/alive if it weren’t here for all that happened in $xbi this year and a half… let’s respect cancer curing breakthrough multi-application combos from these small bios especially $sls given its stellar OS rates and almost at/near completion for multiple trials…

    Shame on shorts acting like vultures on death-defying cures: you may make money now, but when cancer burns inside you or someone you love you will feel the pain…
  • R
    Real Immuno Investor 10
    Hard to Imagine but the market gives $SLS Zero Credit for Nps. Combination Data with Herceptin 8 years in the making Now Imminent for Her2 3+ These are the TNBC results- Notable Correlation Between Progressive Increase of NPS-Specific Cytotoxic T-Lymphocyte in NPS Plus Trastuzumab Patient Cohort and Remaining Clinically Relapse-Free Over Time
    NPS plus trastuzumab-treated TNBC patients exhibited increases in CTL frequencies compared with baseline by 1.1-, 1.73-, and 2.86-fold at 18, 24 and 30 months, respectively. The mean CTL frequencies in these patients increased from 29±0.1 per 10-4 at baseline to 112±2.6% at 30 months, a 2.86-fold difference that was highly clinically indicative (p = 0.058), as compared with patients receiving trastuzumab only, whereby CTL frequencies were 20±0.1 per 10-4 at baseline compared with 52±1.6 per 10-4 at 30 months, a 1.6-fold non-significant difference (p=0.70). Three patients in the combination arm recurred (5.9%) as compared with 12 (30%) in the trastuzumab-alone arm. TNBC patients treated with NPS plus trastuzumab whose disease recurred did not mount an IR by ex vivo assessment (absolute CTL frequency change) or by in vivo DTH (no change in skin induration), while non-recurrent patients mounted both vigorous NPS-specific clonal CTL expansion and enhanced in vivo DTH.
    Bullish
  • V
    ValuFin
    XBI will be obliterated by the democrats bill. If you voted for them because you love the welfare state, then you deserve all the losses.
    Bearish
  • M
    Marx
    Biotechs are close to their 52 week lows and this sector has been hammered badly this year. If you are a contrarian and have patience, this maybe a winner in the first half of the new year.
  • R
    Roshi
    This is a literal joke
  • A
    Andrey
    This is a disgrace to whole market that meme stocks are doing much better this year than biotechs which actually suppose to save lifes. They don't get any real help from the government since "hur dur high prices" but no one cares that these companies have to spend 6-10 years in debt without revenue to start earning money.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Gross end of day BIO TANKAGE $XBI pollution throwing all the Baby Bios out into the street. $SLS will be Among the first to get picked up - So much action coming - $10 is almost a 50% Gain. I am buying More.
    Bullish
  • C
    Chari
    With Russell small cap futures dropping 4% could today be the real capitulations day for XBI? Short trading day though. Hard to expect much happening…
  • C
    Chari
    Was it really capitulation yesterday? I am not sure. If XBI can hold its own today then yes. But chances are it will be weighed down by the broader market now especially the Russell small cap index. May be we will have a black Friday sale followed by a rally on Monday. Certainly getting dragged out this year. Blame it on Covid.
  • M
    Max
    XBI in free fall crashing right back to the levels it was at 7 years ago! 7 years!!! Thanks to politics, FDA corruption, and interest rate fears. Buy Moderna, Gamestop and Dogecoin or lose money. What a joke, what a totally manipulated piece of uninvestible scrap this market has become. I'm out, best of of luck with it. Will buy back into bio when this stinker hits 75 next year. XBI has become a hopeless case.
Advertisement
Advertisement